ReviewCells2022
The Promising Therapeutic and Preventive Properties of Anthocyanidins/Anthocyanins on Prostate Cancer.
Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- A Review on Cyanidin-3-O-glucoside Antioxidant Activity, Food Technology Applications and Therapeutic Uses.Journal of food science · 2026Pooled it
- Role of Cyanidin 3-glucoside Extract in the Induction of Cytotoxicity and Apoptosis in a Rat Bladder Cancer Cell Line.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Genetic Polymorphisms and Antioxidant Reactions in Prostate Cancer.International journal of molecular sciences · 2026Review
- Prostate Cancer, JAK/STAT3 Dysregulation, and Flavonoids: Is There a Possible Link?International journal of molecular sciences · 2026Review
- Anticancer Mechanisms of Bioactive Compounds from Sweet Potato (Foods (Basel, Switzerland) · 2025Review
- Effects of polyphenols on cancer cell progression mediated by inhibition of cyclin-dependent kinases (CDKs): the emerging drug targets in cancer.Archives of pharmacal research · 2025Review
- Integrating metabolomics and transcriptomics comprehensively reveals the global metabolic differences in three species of Nitraria berries.Scientific reports · 2025Article
- Anthocyanins: From Natural Colorants to Potent Anticancer Agents.Food science & nutrition · 2025Review
- Health benefits of anthocyanins against age-related diseases.Frontiers in nutrition · 2025Review
- Protective Effects of Plant-Derived Compounds Against Traumatic Brain Injury.Molecular neurobiology · 2024Review
- Targeting Cancer Hallmarks Using Selected Food Bioactive Compounds: Potentials for Preventive and Therapeutic Strategies.Foods (Basel, Switzerland) · 2024Review
- The Emerging Role of Natural Products in Cancer Treatment.Archives of toxicology · 2024Review
- Unveiling the Antioxidant, Cytotoxic, and Anti-Inflammatory Activities and Chemical Compositional Information of an Invasive Plant:Plants (Basel, Switzerland) · 2024Article
- Integrating natural compounds and nanoparticle-based drug delivery systems: A novel strategy for enhanced efficacy and selectivity in cancer therapy.Cancer medicine · 2024Review
- Exploring Natural Products as Radioprotective Agents for Cancer Therapy: Mechanisms, Challenges, and Opportunities.Cancers · 2023Review
- Article
- Anthocyanins in metabolites of purple corn.Frontiers in plant science · 2023Review
- Cryopreservation of bioflavonoid-rich plant sources and bioflavonoid-microcapsules: emerging technologies for preserving bioactivity and enhancing nutraceutical applications.Frontiers in nutrition · 2023Review
- Properties of flavonoids in the treatment of bladder cancer (Review).Experimental and therapeutic medicine · 2022Review
- Combination Anticancer Therapies Using Selected Phytochemicals.Molecules (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As water-soluble flavonoid derivatives, anthocyanidins and anthocyanins are the plants pigments mostly rich in berries, pomegranate, grapes, and dark color fruits. Many bioactivity properties of these advantageous phytochemicals have been reported; among them, their significant abilities in the suppression of tumor cells are of the promising therapeutic features, which have recently attracted great attention. The prostate malignancy, is considered the 2nd fatal and the most distributed cancer type in men worldwide. The present study was designated to gather the preclinical and clinical studies evaluating potencies of anthocyanidins/anthocyanins for the treatment and prevention of this cancer type for the first time. In general, findings confirm that the anthocyanins (especifically cyanidin-3-O-glucoside) indicated higher activity against prostatic neoplasms compared to their correlated anthocyanidins (e.g., delphinidin); in which potent anti-inflammatory, apoptosis, and anti-proliferative activities were analyzed. Complementary anti-prostate cancer assessment of diverse naturally occurred anthocyanidins/anthocyanins and their synthetically optimized derivatives through preclinical experiments and eventually confirmed by clinical trials can promisingly lead to discover natural-based chemotherapeutic drug options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.